ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET
Company Participants
Lisa Wilson - IR, Insight Communications
Nikhil Lalwani - President, CEO & Director
Christopher Mutz - SVP, Head, Rare Diseases
Stephen Carey - CFO & SVP
Conference Call Participants
Gary Nachman - Raymond James
Faisal Khurshid - Leerink Partners
Vamil Divan - Guggenheim Securities
David Amsellem - Piper Sandler
Ekaterina Knyazkova - J.P. Morgan
Les Sulewski - Truist Securities
Operator
Please stand by. Your program is about to begin. [Operator Instructions] Good day everyone and welcome to today's ANI Pharmaceuticals, Inc. First Quarter 2025 Earnings Results Call. Please note this call is being recorded. After the speakers’ opening remarks, there will be a question-and-answer session. [Operator Instructions]
It is now my pleasure to turn the conference over to Lisa Wilson.
Lisa Wilson
Thank you, operator. Welcome to ANI Pharmaceutical's Q1 2025 Earnings Results Call. This is Lisa Wilson, Investor Relations for ANI. With me on today's call are Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Chris Mutz, Senior Vice President and Head of ANI's Rare Disease Business. You can also access the webcast of this call through the Investor section of the ANI website at anipharmaceuticals.com.
Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to ANI Pharmaceuticals Management, as of today and involve risks and uncertainties including those noted in our press release issued this morning and our filings with the SEC.
Such forward-looking statements are not
- Read more current ANIP analysis and news
- View all earnings call transcripts